Stromal Derived Factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Pan, Judong ^a   Mestas, Javier ^a   Burdick, Marie D ^a   Phillips, Roderick J ^a   Thomas, George V ^a   Reckamp, Karen ^a   Belperio, John A ^a   Strieter, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1; TUMOR SUPPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL HYPOXIA; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CHEMOKINE CXCL12; CHEMOKINES, CXC; CHEMOTAXIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KERATINS; KIDNEY NEOPLASMS; MICE; MICE, SCID; PROMOTER REGIONS, GENETIC; RECEPTORS, CXCR4; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33751319000     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-56     Document Type: Article

References (64)

1. American Cancer Society: Cancer Facts and Figures 2004: Selected Cancers Am Cancer Soc; 2004.
2. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA: Renal cell carcinoma with retroperitoneal lymph nodes, Impact on survival and benefits of immunotherapy. Cancer 2003, 97:2995-3002.
3. Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980, 40:2281-2287.
4. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14:171-179.
5. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004, 35:233-245.
6. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
7. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003, 167:1676-1686.
8. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004, 14:181-185.
9. Baggiolini M: Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
10. Power CA, Wells TN: Cloning and characterization of human chemokine receptors. Trends Pharmacol Sci 1996, 17:209-213.
11. Premack BA, Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nat Med 1996, 2:1174-1178.
12. Rossi D. Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
13. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
14. Balkwill F: Chemokine biology in cancer. Semin Immunol 2003, 15:49-55.
15. Murphy PM: Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001, 345:833-835.
16. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
17. Horuk R: Chemokine receptors. Cytokine Growth Factor Rev 2001, 12:313-335.
18. Moepps B, Braun M, Knopfle K, Dillinger K, Knochel W, Gierschik P: Characterizadon of a Xenopus laevis CXC chemokine receptor 4: implications for hematopoietic cell development in the vertebrate embryo. Eur J Immunol 2000, 30:2924-2934.
19. Ma Q, Jones D, Springer TA: The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999, 10:463-471.
20. Luster AD: Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436-445.
21. Ma Q, Jones D, Borghesani PR, Segal PA Nagasawa T, Kishimoto T, Bronson RT, Springer TA. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci U S A 1998, 95:9448-9453.
22. Nagasawa. T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
23. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K. Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al.: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
24. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
25. Bachelder RE, Wendt MA, Mercurio AM: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002, 62:7203-7206.
26. Bonavia R, Bajetto, A, Barbero S, Pirani P, Florio T, Schettini G: Chemokines and their receptors in the CNS: expression of CXCL12/SDF-1 and CXCR4 and their role in astrocyte proliferation. Toxicol Lett 2003, 139:181-189.
27. Majka M, Ratajczak J, Kowalska MA, Ratajczak MZ: Binding of stromal derived factor-1 alpha (SDF-1 alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42/44 (MAPK), ELK-1 transcription factor and serine/threonine kinase AKT. Eur J Haematol 2000, 64:164-172.
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
29. Salcedo R, Oppenheim JJ: Role of chemokines in angiogenesis: CXCL12/ SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003, 10:359-370.
30. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human enclothelial cells: In vivo neovascularization induced by stromal-derived factor-1 alpha. Am J Pathol 1999, 154:1125-1135.
31. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003, 89:462-473.
32. Zhou Y, Larsen PH, Hao C, Yong VW: CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002, 277:49481-49487.
33. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, et al.: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003, 198:1391-1402.
34. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 2003, 425:307-311.
35. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, Keane MP, Strieter RM: EGF and hypoxia-induced expression of CXCR4 on non-small cell lung cancer cells is regulated by the P13-kinase/PTEN/ AKT/mTOR signaling pathway and activation of HIF-1 alpha. J Biol Chem 2005.
36. Gomperts BN, Belperio, JA, Rao PN, Randell SH, Fishbein MC, Burdick MD, Strieter RM: Circulating Progenitor Epithelial Cells Traffic via CXCR4/ CXCL12 in Response to Airway Injury. J Immunol 2006, 176:1916-1927.
37. Korbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z: Hepatocytes; and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002, 346:738-746.
38. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114:438-446.
39. Amato RJ: Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005, 16:7-15.
40. Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, et al.: CXCR4/ CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002, 86:1250-1256.
41. Bauernhofer T, Zenahlik S, Hofmann G, Balic M, Resel M, Pirchmoser R, Regitnig P, Ambros P, Dandachi N, Samonigg H: Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol Rep 2005, 13:179-184.
42. Blumke K, Bilkenroth U, Schmidt U, Melchior A, Fussel S, Bartel F, Heynemann H, Fornara P, Taubert H, Wirth MP, Meye A: Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol Rep 2005, 14:895-899.
43. Ratajczak MZ, Kucia M, Reca R, Majka M, Janowska-Wieczorek A, Ratajczak J: Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow. Leukemia 2004, 18:29-40.
44. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga. L, Ali MA, Melamed J, Semenza GL: Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005, 65:6178-6188.
45. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, Parmentier M, Arenzana-Seisdedos F: Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 1998, 426:271-278.
46. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDCI in T lymphocytes. J Biol Chem 2005, 280:35760-35766.
47. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
48. Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578.
49. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
50. Wood SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH, Ratcliffe PJ: Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1 alpha). Characterization of hif-1 alpha-dependent and -independent hypoxia-inducible gene expression. J Biol Chem 1998, 273:8360-8368.
51. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996, 93:10589-10594.
52. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595-10599.
53. Rini BI: VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 2005, 10:191-197.
54. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP: AMD3100 a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998, 4:72-77.
55. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. Aids 2002, 16:2385-2390.
56. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi JP, Fujii N, Broach JR, Peiper SC: A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 2002, 277:24515-24521.
57. Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, Labrecque J, Lau G, Mosi RM, Nelson KL, et al.: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006, 72:588-596.
58. Westergaard MH, Thrue HF, Hansen CA, Kjaerulff JB, Straarup LS, Olsen EM, Dalby O, Hildebrandt LW, Eriksen L, Kearney P: SPC2968 - A novel Hif-1 antagonist for treatment of clear cell renal cell carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 2006.
59. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM: The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000, 11:247-261.
60. Naito S, Walker SM, Fidler IJ: In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice. Clin Exp Metastasis 1989, 7:381-389.
61. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122-127.
62. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM: Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998, 102:465-472.
63. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996, 97:2792-2802.
64. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996, 184:981-992.